This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?
by Zacks Equity Research
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
Novartis (NVS) Benefits From New Drugs & Key Acquisitions
by Zacks Equity Research
Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.
Teva Stock Rises on Patent Settlement With Neos Therapeutics
by Zacks Equity Research
Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019
by Kinjel Shah
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
by Zacks Equity Research
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer
by Zacks Equity Research
Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.
Aduro Stock Surges on STING Activator Deal With Eli Lilly
by Zacks Equity Research
Aduro (ADRO) inks a collaboration/license deal with Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
Tilray Stock Up on Medical Cannabis Collaboration With Sandoz
by Zacks Equity Research
Tilray (TLRY) expands its previous collaboration deal with Sandoz, a generic arm of Novartis, to supply medical cannabis globally using the latter's supply chain.
Company News For Dec 19, 2018
by Zacks Equity Research
Companies In The News Are: CBS,BA,DRI,TLRY,NVS
Glaxo, Pfizer to Merge Consumer Health Units, Form New JV
by Zacks Equity Research
Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.
What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL
by Ryan McQueeney
Ryan McQueeney recaps news involving the U.S. housing market, Tilray, Johnson & Johnson, and Oracle. Later, the host provides an outlook for General Electric stock in 2019.
Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
by Zacks Equity Research
Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.
Teva Reports Positive Top-Line Data for Migraine Candidate
by Zacks Equity Research
Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.
Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug
by Zacks Equity Research
Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.
J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed
by Zacks Equity Research
J&J's (JNJ) board authorizes a $5-billion share repurchase plan. Stock slips 2.9% on Monday, extending a 10% drop on Friday post publication of a controversial Reuters story.
Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
by Zacks Equity Research
Roche's (RHHBY) investigational oral medicine risdiplam gets PRIME designation for the treatment of SMA.
Incyte (INCY) Collaborates with Innovent for 3 Candidates
by Zacks Equity Research
Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
by Zacks Equity Research
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
Teva (TEVA) Stock Poised to Record Big Gains in 2019?
by Zacks Equity Research
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
by Zacks Equity Research
Amgen (AMGN) hikes its quarterly dividend by 10%.
Novartis Presents Additional Data on Breast Cancer Candidate
by Zacks Equity Research
Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.